

Hepatitis D Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

https://marketpublishers.com/r/H736CB4776F7EN.html

Date: October 2019 Pages: 50 Price: US\$ 1,699.00 (Single User License) ID: H736CB4776F7EN

Abstracts

Hepatitis D Drug pipeline report- 2020 is an annual R&D review of Hepatitis D pipeline candidates. The report presents the current status of all major Hepatitis D therapeutic compounds. Detailed insights into Hepatitis D pipeline development, current status, companies, drug profiles and Hepatitis D preclinical and clinical trials are included.

2020 Hepatitis D Pipeline Market Insights

Hepatitis D disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Hepatitis D therapies, pipeline by phase and others are included.

Hepatitis D pipeline Drug profiles-

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Hepatitis D Therapeutic Drug candidates Both active and inactive Hepatitis D pipeline drug candidates are included in the report

Hepatitis D Clinical Trials and preclinical Studies

Hepatitis D In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.



Hepatitis D pipeline market developments

Hepatitis D Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Hepatitis D pipeline companies in active development The report analyzes Hepatitis D pipeline of the below companies-

CN Bio Innovations Ltd, ContraVir Pharmaceuticals Inc, Eiger BioPharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Globeimmune Inc, Merck & Co Inc, MYR GmbH, Replicor Inc, Rodos BioTarget GmbH, SomaGenics Inc

Report Coverage

What to look out for in 2020 Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

10 Companies investing in Hepatitis D pipeline from discovery stage to pre-registration phase are included

Drug profiles Over 10 details of each Hepatitis D pipeline candidate are included

Company Profiles Business overview and contact details of all companies operating in the industry are provided

Market Developments News, Developments and other recent industry developments are included



Contents

1. HEPATITIS D PIPELINE MARKET INSIGHTS, 2020

- 1.1 Hepatitis D Disease Overview
- 1.2 Hepatitis D Drug Pipeline Snapshot, 2020
- 1.2.1 Hepatitis D Pipeline Drugs by Phase
- 1.2.2 Hepatitis D Pipeline Drugs by Company
- 1.2.3 Hepatitis D Pipeline Drugs by Mechanism of Action
- 1.2.4 Hepatitis D Pipeline Drugs by Route of Administration

2. HEPATITIS D COMPANY WISE PIPELINE DETAILS

CN Bio Innovations Ltd Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details** ContraVir Pharmaceuticals Inc Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details** Eiger BioPharmaceuticals Inc Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details** F. Hoffmann-La Roche Ltd Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details** Globeimmune Inc Hepatitis D Pipeline Drugs **Company Profile** Drug Candidate Details Merck & Co Inc Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details** MYR GmbH Hepatitis D Pipeline Drugs **Company Profile Drug Candidate Details Replicor Inc Hepatitis D Pipeline Drugs Company Profile Drug Candidate Details** Rodos BioTarget GmbH Hepatitis D Pipeline Drugs **Company Profile**



Drug Candidate Details SomaGenics Inc Hepatitis D Pipeline Drugs Company Profile Drug Candidate Details

3. HEPATITIS D DRUG PIPELINE PROFILES

- 3.1 Discovery and Preclinical Drug Profiles
- 3.2 Phase 1 Drug Profiles
- 3.3 Phase 2 Drug Profiles
- 3.4 Phase 3 Drug Profiles

4. HEPATITIS D PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

- 5.1 Primary and Secondary Research Methodology
- 5.2 Publisher Expertize
- 5.3 Contacts



I would like to order

Product name: Hepatitis D Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs
 Product link: https://marketpublishers.com/r/H736CB4776F7EN.html
 Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

 If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/H736CB4776F7EN.html</u>